On Apr. 23, 2020, AstraZeneca and and Saint Lukeﾒs Mid America Heart Institute initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure.